Skip to main content
Premium Trial:

Request an Annual Quote

Microsaic H1 2013 Revenues Double

NEW YORK (GenomeWeb News) – Miniature mass spectrometry firm Microsaic Systems today reported that revenues for the first half of the year doubled year over year.

The UK firm posted revenues of £541,529 ($873,645) in the recently completed six month period, up from £269,992, driven by product sales growth, Microsaic said.

Total comprehensive loss for the six months was £1.0 million, or 2.6 pence per share, up from a loss of £789,832, or 2.0 pence, a year ago.

Microsaic said total operating expenses more than doubled to £784,768 — which included £582,591 in R&D spending — from £378,067 in the year-ago period.

It finished the first half of 2013 with £4.8 million in cash and cash equivalents.

Highlights for H1 2013 included the launch of the Microsaic 4000 MiD miniature mass spec, and the completion of a £4.28 million fund raising. Also, Microsaic's original equipment manufacturing partner, Biotage, launched the Isolera Dalton, a fully integrated system for flash chromatography and mass identification incorporating the 4000 MiD.

In a statement, Microsaic Chief Executive Colin Jump said the market reception to both platform launches has been positive. "This growing traction and the progress we are making in discussions with potential partners and customers confirm to the board that there is significant demand for our products across multiple application areas and formats."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.